Bluejay Investor Presentation Deck

Bluejay Diagnostics: Optimizing Turnaround Times to Improve Patient Outcomes Novel Proprietary Platform Symphony™ Product Lead Candidate: IL-6 Assay Market Opportunity Commercial Strategy Capital Efficient Model DIAGNOSTICS >> >> >>> >> Uses whole blood (no pre-processing) Results in less than 20 minutes Completed initial clinical studies for measuring IL-6 in critical care settings to support de novo FDA Marketing Application Symphony™ Product Pipeline addresses multi-billion-dollar market Near-patient testing (NPT) for monitoring of disease progression Large, well-respected clinical testing sites are built-in commercial customers Reagent-rental model and DRG-based reimbursement simplifies adoption for hospitals $13.3MM cash as of Sept 30, 2022, sufficient to fund operations for next 12 months The SymphonyTM System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA Copyright ©2022 Bluejay Diagnostics, Inc. All rights reserved in all slides | October 2022 3

View entire presentation